Core Points - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. has announced the progress of its second share repurchase plan, revealing that as of November 30, 2025, no shares have been repurchased, representing 0.00% of the company's total share capital [1][3] Summary by Sections Repurchase Plan Overview - The second share repurchase plan was approved by the company's board on October 28, 2025, with a maximum repurchase price set at 21.06 CNY per share, which is 150% of the average trading price over the previous 30 trading days [2] - The expected number of shares to be repurchased ranges from 2.1 million to 2.4 million shares, with a total estimated repurchase fund not exceeding 50.544 million CNY [2] Implementation Progress - As of November 30, 2025, the company has not conducted any repurchase operations, citing market conditions as the reason for the lack of activity [3] - The company is adhering to regulations regarding share repurchases, including avoiding repurchases during significant market events or periods prohibited by regulatory authorities [3] Future Plans - The company intends to continue pursuing the repurchase plan within the designated timeframe and will fulfill its information disclosure obligations as required by law [4] - The implementation of the repurchase plan may face uncertainties, and the company has previously disclosed multiple share repurchase plans, indicating ongoing market interest [4]